Halma Acquires Lamidey Noury Medical in £42m Deal

On Monday, Halma (LON: HLMA) announced the acquisition of Lamidey Noury Medical in a £42 million deal.

Lamidey Noury, a French medical device company, specialises in advanced electrosurgical and energy devices used in minimally invasive surgeries.

The company’s products are distributed to healthcare providers in over 60 countries.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

The acquisition, funded by FTSE 100 firm Halma’s existing facilities, will see Lamidey Noury operate as a standalone company within Halma’s Healthcare Sector. The company’s revenue for the past year reached £11.4 million, with an EBIT margin exceeding Halma’s target range.

Marc Ronchetti, Halma’s Group Chief Executive, expressed enthusiasm for the acquisition, highlighting Lamidey Noury’s potential to enhance Halma’s Healthcare Sector.

“Lamidey Noury is an exciting acquisition which will bring new minimally invasive surgical product capabilities to our Healthcare Sector,” said Ronchetti.

He added: “Its advanced products improve patient outcomes and the efficiency of healthcare providers in treating the increasing incidence of urological and gynaecological disease. It is adjacent to our existing presence in diagnosis and biopsy devices for these diseases through Rovers Medical Devices and IZI Medical.”

Guillaume Noury, President of Lamidey Noury, also welcomed the deal, stating that joining Halma will accelerate the company’s growth and innovation.

“We are confident in our ability to continue delivering high-quality surgical tools to our customers worldwide while providing new opportunities for our employees and stakeholders,” stated Noury.